Hyperhomocyst(e)inemia and Endothelial Dysfunction in IDDM
- 1 May 1998
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 21 (5) , 841-848
- https://doi.org/10.2337/diacare.21.5.841
Abstract
OBJECTIVE Considering that elevated blood levels of homocyst(e)ine represent a known independent risk factor for macrovascular disease, we assessed the link between hyperhomocyst(e)inemia and diabetic microvascular complications. RESEARCH DESIGN AND METHODS Homocyst(e)ine and thrombomodulin plasma levels, a marker of endothelial cell damage, were measured before and 3 h after oral methionine loading in 75 patients with stable, well-controlled IDDM and 40 healthy control subjects matched for sex and age. Exclusion criteria were hyperlipidemia, hypertension, smoking, or positive family history for cardiovascular disease. RESULTS IDDM patients had higher pre- and postload homocyst(e)ine plasma levels than did healthy control subjects (12.0 vs. 7.7 umol/1 and 27.6 vs. 16.0 umol/1; P < 0.001). Of 75 IDDM patients, 26 had homocyst(e)ine plasma levels above the normal range (defined as mean ± 2 SD of values obtained in the control group). The IDDM patients with hyperhomocyst(e)inemia had higher thrombomodulin plasma levels (62.2 vs. 38.2 ng/ml; P < 0.001), higher albumin excretion rates (485 vs. 115 mg/1; P < 0.005), and a higher prevalence of late diabetic complications (nephropathy 76 vs. 33%; retinopathy 69 vs. 51%; neuropathy, 57 vs. 41%; macroangiopathy 57 vs. 33%) compared with IDDM patients with normal plasma homocyst(e)ine. In vitro experiments with human umbilical vein cells show an increased release of thrombomodulin into the culture supernatant only when endothelial cells were pretreated with advanced glycation end product (AGE)-albumin before L-homocystine was added. A synergistic action of homocyst(e)ine and AGEs might contribute to vascular complications of patients with diabetes. CONCLUSIONS Hyperhomocyst(e)inemia is common in nephropathic diabetic patients and may contribute to the enhanced morbidity and mortality from cardiovascular diseases characteristically observed in IDDM patients with diabetic nephropathy.This publication has 9 references indexed in Scilit:
- Oxidative Stress and Diabetic Vascular ComplicationsDiabetes Care, 1996
- Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trialThe American Journal of Cardiology, 1995
- Lymphocytic Infundibuloneurohypophysitis as a Cause of Central Diabetes InsipidusNew England Journal of Medicine, 1993
- Plasma thrombomodulin concentration in diabetes mellitusDiabetes Research and Clinical Practice, 1990
- HOMOCYSTEINE, AN ATHEROGENIC STIMULUS, REDUCES PROTEIN-C ACTIVATION BY ARTERIAL AND VENOUS ENDOTHELIAL-CELLS1990
- Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease Effects of pyridoxine and folic acid treatmentAtherosclerosis, 1990
- Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine.Journal of Clinical Investigation, 1986
- Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C.Proceedings of the National Academy of Sciences, 1981
- Homocysteine-induced endothelial cell injury in vitro: A model for the study of vascular injuryThrombosis Research, 1980